The efficacy of a novel, dual PI3K/mTOR
β
Niranjan Awasthi; Peter L. Yen; Margaret A. Schwarz; Roderich E. Schwarz
π
Article
π
2012
π
John Wiley and Sons
π
English
β 419 KB
## Abstract Gemcitabine has limited clinical benefits for pancreatic ductal adenocarcinoma (PDAC). The phosphatidylinositolβ3βkinase (PI3K)/AKT and mammalian target of rapamycin (mTOR) signaling pathways are frequently dysregulated in PDAC. We investigated the effects of NVPβBEZ235, a novel dual PI